-
- ADME/DMPKDrug Efficacy Testing
- Cerebral Infarct Size Measurement
- Histological Assessment
- Physiological Monitoring
- Behavioral TestingBrain Imaging
- Cerebral Blood Flow Monitoring
- Brain Edema Measurement
- Assessment of Blood-Brain Barrier
- Assessment of Leukocyte-Platelet Aggregates
- Quantitative Analysis of Protein and mRNA Expression
Safety AssessmentIn Vitro Pharmacology- Cell Viability Assay
- Caspase-3 Activity Assay
- In Vitro Neuroinflammatory Models and Assays
- Excitotoxicity In Vitro Assay
- Cell-Based Mitochondrial Function Assay
- In Vitro Oxidative Stress Assay
- Ischemia-Triggered Glutamate Excitotoxicity
- NMDA Receptor-mediated Excitotoxicity
- AMPA Receptor-mediated Excitotoxicity
Molecular Mechanism of Oxidative StressNeuroinflammatory Mechanisms- Ischemia-Reperfusion Injury
Cell Death Mechanism- Autophagy MechanismApoptotic Mechanism
- Ferroptosis Pathways
- Necroptosis Signaling Pathways
Epigenetic Mechanism- Gut Microbiota
- Animal Modeling of Stroke
- Animal Modeling of Ischemic StrokeAnimal Modeling of Hemorrhagic StrokeIn Vitro Modeling of Stroke
- In Vitro Modeling of Ischemic Stroke
- In Vitro Modeling of Hemorrhagic Stroke
- Small-Molecule Antiplatelet DrugsNeuroprotective PeptidesMonoclonal Antibodies for StrokeStem Cell-Based Therapies for StrokeDrug Delivery SystemsInquiry
Stroke-Related Metabolite Biomarker Development Services
Ischemic brain injury is extremely complex and involves a range of pathological processes. Metabolite disorders are considered to be important factors in ischemic stroke. Recently, metabolomics studies have provided new insights into the discovery of stroke biomarkers. Metabolomics is a powerful method to directly represent biomolecular phenotypes and is increasingly used to discover sensitive biomarkers for disease diagnosis and personalized therapy. Related studies have mainly focused on identifying significant metabolites in biofluids to reveal systemic metabolic changes caused by cerebral ischemia but have not actively promoted the simplification or verification of metabolites indicative of the disease.
Fig. 1. Metabolomics: A useful tool for ischemic stroke research. (Li et al., 2023)Our Services
As a leading contract research service provider in the field of stroke, Ace Therapeutics utilizes bioanalytical capabilities to support your metabolite biomarker development. With experience and expertise in biomarker development and validation, our team offers biomarker development services based on metabolomics technologies to support your basic stroke research and drug development efforts.
Types of Stroke-Related Metabolite Biomarkers We Can Develop
We offer nuclear magnetic resonance (NMR) or mass spectrometry (MS)-based metabolomics technologies to characterize the metabolic profile of stroke animals to identify novel sensitive biomarkers for diagnosis and progression. We can assist our clients in the development and analytical validation of a wide range of metabolites associated with stroke.
Type of Metabolites Examples Metabolite biomarkers associated with excitotoxicity Glutamate, glutamine, phenylalanine, tyrosine, homocysteine, methionine, tryptophan, aspartate, alanine, proline, pyroglutamate Metabolites biomarkers associated with oxidative stress Hypoxanthine, lactate, uric acid, metalloproteinase (MMP), sphingosine 1-phosphate, homocysteine, formate, glucolate, tetrahydrofolate, oxidized glutathione, dimethylarginine, malonic acid, glycine, gamma-glutamyltransferase (GGT), valine, isoleucine, hippurate, methanol Metabolite biomarkers associated with inflammation Kynurenine, lysophosphatidylethanolamine (LysoPE), phosphatidylserine, phosphatidylethanolamine (PE), phosphatidylcholine (PC), lysophosphatidylcholines, tryptophan, 3-indole propionic acid How to Develop Stroke-Related Metabolite Biomarkers
Metabolite Biomarker Discovery
- We use standardized extraction and sample preparation methods (e.g., protein precipitation, liquid-liquid extraction) to extract metabolites from blood, cerebrospinal fluid, or brain tissue of animal origin.
- We use high-throughput metabolomics techniques (e.g., GC-MS, LC-MS, etc.) to detect and quantify the extracted metabolites.
- Changes in the concentration of various small molecule metabolites in the samples are comprehensively determined, and the metabolic profiling data obtained are statistically analyzed using bioinformatics tools.
- By comparing metabolite levels in animal stroke models and healthy controls, we can help our clients screen for candidate markers with significant differences.
Metabolite Biomarker Validation
- We use independent biochemical assays (e.g. ELISA, enzyme activity assays) for further validate differential metabolites.
- We help our clients to investigate the relationship between the differential metabolites and the pathogenesis of stroke and to elucidate their biological functions.
- We use in vitro and animal models of stroke to validate the role of these metabolite biomarkers in the pathogenesis of stroke.
By analyzing aberrant metabolic pathways in stroke, Ace Therapeutics aims to help clients develop effective metabolite biomarkers and analyze the molecular processes in stroke to develop novel stroke treatment strategies. Whether it is early screening of metabolite biomarkers or large-scale validation of metabolite biomarkers, we can provide the specialized technology platform and services to meet clients' needs. Please contact us for high-quality biomarker development services.
Reference- Li, W., Shao, C., et al. (2023). Metabolomics: A useful tool for ischemic stroke research. Journal of Pharmaceutical Analysis.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket